Target early-stage biotech Limited current headcount (0-1) and UC Berkeley spinout status indicate a small team with high potential dependency on external partnerships and rapid prototyping needs; tailor outreach to offer affordable, scalable diagnostic instrument integration and rapid pilot programs.

Point-of-care focus Emphasize solutions that enable rapid, low-cost DNA/RNA diagnostics at or near the patient; position offerings as enabling faster go-to-market for molecular diagnostics with minimal operational disruption.

Cost-conscious buyers Revenue under $1M and similar-market players show budget sensitivity; propose modular, cost-effective technology stacks, flexible licensing, and pilot-ready packages to minimize upfront investment.

Strategic partnerships Existing ecosystem includes microfluidics and diagnostic peers; propose co-development, academic collaboration, or technology licensing with nearby competitors to accelerate validation and market entry.

Tech and compliance readiness Tech stack familiarity with web-based tools and security measures (Cloudflare, reCAPTCHA, JSON-LD) suggests readiness for cloud-enabled data workflows; offer compliant data management, cloud integration, and cybersecurity considerations to support scale.